“We’re excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte’s versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics,” said Doug Doerfler, President & CEO of MaxCyte, Inc.
The expansion of the Kite-MaxCyte relationship builds on an existing research agreement announced in November 2018. Under the terms of the new license agreement, Kite obtains non-exclusive clinical and commercial-use rights to MaxCyte’s cell engineering platform to develop CAR-T therapies, and MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.
MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase 1 clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com
For further information, please contact:
|MaxCyte Inc.||+1 301 944 1660|
Jamie Lacey-Moreira +1 410 299 3310
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter